Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Interest Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Interest Expenses for 9 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 42.89% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.9 million, a 46.85% decrease, with the full-year FY2025 number at $60.9 million, down 46.87% from a year prior.
  • Interest Expenses was $14.8 million for Q4 2025 at ImmunityBio, down from $15.3 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $35.0 million in Q3 2023 to a low of -$18.7 million in Q4 2022.
  • A 5-year average of $16.8 million and a median of $15.4 million in 2025 define the central range for Interest Expenses.
  • Biggest YoY gain for Interest Expenses was 363.86% in 2022; the steepest drop was 515.43% in 2022.
  • ImmunityBio's Interest Expenses stood at $4.5 million in 2021, then tumbled by 515.43% to -$18.7 million in 2022, then soared by 270.36% to $31.8 million in 2023, then decreased by 18.21% to $26.0 million in 2024, then tumbled by 42.89% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Interest Expenses are $14.8 million (Q4 2025), $15.3 million (Q3 2025), and $15.5 million (Q2 2025).